Benzinga · Sep 8, 2026
BTIG Maintains Buy on Absci, Raises Price Target to $16
BTIG analyst Kambiz Yazdi maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $13 to $16.
AB
NASDAQ · ABSI
Absci Corporation
Healthcare · Biotechnology
$7.94
Up+$0.13 (+1.58%)
Updated Sep 16, 2026, 3:08 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 412.02M
- P/E ratio
- -3.44
- Dividend yield
- 0.00%
- 52-week range
- $2.24 – $12.06
- Volume
- 2.34M
- Avg. volume
- 3.49M
Price performance
ABSI price history
1M range · 20 trading sessions · Daily adjusted prices
ABSI closed at $7.94 after 20 trading sessions, down 10.28% for the selected period.
- Last close
- $7.94
- Period change
- -10.28%
- Period low
- $7.94
- Period high
- $9.99
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $8.055 | $8.07 | $7.79 | $7.94 | 2.34M |
| Sep 14, 2026 | $8.03 | $8.25 | $8.02 | $8.09 | 3M |
| Sep 11, 2026 | $8.42 | $8.57 | $8.11 | $8.21 | 1.97M |
| Sep 10, 2026 | $8.375 | $8.56 | $8.0198 | $8.24 | 3.09M |
| Sep 9, 2026 | $8.89 | $9.02 | $8.625 | $8.65 | 2.03M |
| Sep 8, 2026 | $8.82 | $9.10 | $8.57 | $8.91 | 2.51M |
| Sep 4, 2026 | $8.69 | $9.03 | $8.65 | $8.82 | 2.15M |
| Sep 3, 2026 | $8.91 | $8.9953 | $8.55 | $8.80 | 2.75M |
| Sep 2, 2026 | $8.90 | $9.23 | $8.36 | $8.80 | 2.95M |
| Sep 1, 2026 | $8.85 | $9.08 | $8.711 | $8.84 | 3.24M |
| Aug 31, 2026 | $8.67 | $9.09 | $8.6198 | $9.04 | 5.26M |
| Aug 28, 2026 | $9.202 | $9.30 | $8.60 | $8.71 | 2.51M |
| Aug 27, 2026 | $9.28 | $9.6788 | $9.155 | $9.42 | 3.21M |
| Aug 26, 2026 | $9.555 | $9.65 | $8.90 | $9.22 | 2.68M |
| Aug 25, 2026 | $9.11 | $9.705 | $9.10 | $9.63 | 2.34M |
| Aug 24, 2026 | $9.33 | $9.36 | $8.75 | $8.84 | 2.2M |
| Aug 21, 2026 | $9.56 | $9.90 | $9.50 | $9.55 | 2.33M |
| Aug 20, 2026 | $9.74 | $10.03 | $9.24 | $9.28 | 2.91M |
| Aug 19, 2026 | $9.42 | $10.015 | $9.35 | $9.99 | 4.53M |
| Aug 18, 2026 | $8.87 | $9.14 | $8.55 | $8.85 | 2.48M |
Latest ABSI news
The latest Smart Investors Daily articles mentioning ABSI.
Stock researchCompany · Overview
ABSI research
Overview
Company profile and research snapshot.
Company profile
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | LifeSci Capital | Outperform | — |
| Sep 8, 2026 | BTIG | Buy | — |
| Aug 12, 2026 | Needham | Buy | — |
| Aug 12, 2026 | BTIG | Buy | — |
| Jul 2, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 1, 2026
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment Conference (New York, NY) Fireside chat on Tuesday, September 15th at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time Morgan Stanley 24th Annual Gl
Yahoo · Aug 31, 2026
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s.
SeekingAlpha · Aug 20, 2026
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
